SangeethaReddyMD

Oncology • Dallas, TX

Hematologic Oncology

Physician

Join to view full profile

Dr. Reddy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Reddy's full profile

Already have an account?

Office
5323 Harry Hines Boulevard
Dallas, TX 75390
Phone+1 214-645-4673

Fax+1 214-645-7316

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
McGaw Medical Center of Northwestern UniversityChief Residency, Internal Medicine, 2013 - 2014
Northwestern UniversityMSci, Clinical Investigation, 2012 - 2014
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2011 - 2013
McGaw Medical Center of Northwestern UniversityInternship, Internal Medicine, 2010 - 2011
David Geffen School of Medicine at UCLAClass of 2010

Certifications & Licensure

TX State Medical License 2014 - 2025
IL State Medical License 2010 - 2014

Clinical Trials

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib Start of enrollment: 2021 Apr 15
Recruiting
Phase 2

Publications & Presentations

PubMed

6 citations
A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response.
Lily Xu, Kaitlyn Saunders, Shao-Po Huang, Hildur Knutsdottir, Kenneth Martinez-Algarin
Cell Reports. Medicine. 2024-05-21
Digital droplet PCR analysis of organoids generated from mouse mammary tumors demonstrates proof-of-concept capture of tumor heterogeneity.
Katherine E Lake, Megan M Colonnetta, Clayton A Smith, Kaitlyn Saunders, Kenneth Martinez-Algarin
Frontiers in Cell and Developmental Biology. 2024-01-01
6 citations
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.
Amrendra Kumar, Vijay Ramani, Vijaya Bharti, Daniel de Lima Bellan, Nabil Saleh
Journal for Immunotherapy of Cancer. 2023-05-01

Press Mentions

Neoadjuvant Nivolumab/Ipilimumab Combo Effective but Toxic for MelanomaNovember 12th, 2017
Three Workshops Among Several Focusing on Clinical ScienceNovember 29th, 2023